Amazon and GoodRx Storm the Healthcare Market: Flat-Fee Prescriptions as New Business Model

Amazon and GoodRx are recording growing customer numbers in their prescription subscription services, while millions of Americans abandon their traditional health insurance due to rising premiums. Both companies' subscription models offer access to prescription medications at monthly flat rates, independent of classical insurance structures.

Health Insurance Premiums Rise Sharply

ACA (Affordable Care Act) health insurance premiums rose by more than 20 percent in 2026: An analysis by the Commonwealth Fund dated January 15, 2026 puts the increase in benchmark premiums at 21.7 percent. According to calculations by KFF (Kaiser Family Foundation), insurers raised their premiums on ACA marketplaces in 2026 by an average of around 26 percent. Employer-sponsored private insurance is expected to become up to 11 percent more expensive in 2027, according to a WTW study from September 2026.

In response, millions of Americans cancelled their individual ACA insurance plans, Reuters reported on September 29, 2026. William Soliman, Chief Investment Officer at White Manna Capital Partners, noted that insured individuals with high deductibles increasingly compare insurance prices with direct cash payment options.

Amazon RxPass Records Nearly Threefold User Growth

Amazon launched RxPass in 2023 as an add-on service to its Amazon Pharmacy. The number of users has nearly tripled since launch, as John Love, Vice President at Amazon Pharmacy, stated on September 29, 2026. More than 70 percent of users obtain three or more different medications through the service.

RxPass costs $5 per month and covers a range of common prescription medications. According to analyst assessments, the fixed price is easier for consumers to understand than changing coverage structures and deductibles of traditional insurance – an advantage in times of rising and opaque healthcare costs.

GoodRx Launches Companion Plan

GoodRx introduced its Companion subscription plan in May 2026. For $14.99 per month, customers receive discounts on prescription medications, free access to over 250 generic drugs, and discounted healthcare services.

The company thereby positions itself as an alternative to classical insurance models and targets the growing group of consumers who perceive traditional health insurance as too expensive or inflexible.

Disruption of the US Healthcare Market

Amazon and GoodRx deliberately exploit structural disruptions in the US health insurance market. Both companies explicitly address consumers who reduce or abandon their insurance coverage. The subscription models offer predictable monthly costs instead of hard-to-calculate premiums, deductibles, and variable copayments.

For private investors in the DACH region, this represents an example of business model innovation in a regulated market: While the European healthcare market is heavily state-organized, new commercial opportunities emerge in the US from gaps in healthcare provision. Amazon leverages its logistics infrastructure and customer base, while GoodRx draws on its established position in the pharmacy discount business.

Market Outlook and Implications

The rising demand for prescription subscriptions reflects a fundamental shift in the US healthcare market. If insurance premiums continue to rise while cheap direct offerings become available, the classical insurance model may lose appeal for chronically ill patients with predictable medication needs.

Amazon benefits from its existing Prime infrastructure and can integrate medication delivery as an additional service. GoodRx is expanding its business model from pure discount codes to comprehensive healthcare services. Both companies, however, face direct competition with each other and with established pharmacy chains that are also developing subscription models.

Whether flat-rate prescriptions will establish themselves as an independent business model in the long term or whether regulatory intervention will slow expansion remains to be seen. However, current growth figures show that demand exists and traditional insurers face mounting pressure.